NL-OMON46311已完成不适用
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NPT189 in Healthy Subjects - Phase 1 Single Ascending Dose Study Evaluating NPT189 in Healthy Volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Healthy male or female subjects
- •-18-65 yrs, inclusive
- •-BMI: 18-32 kg/m2, inclusive
- •-Weight >= 45kg and <= 120kg
- •-Non-smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
终止
1 期
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Dose or Multiple Dose Study of KHK4323 in Healthy Volunteers, and Subjects with Atopic DermatitisAtopic dermatitisJPRN-jRCT2080224566Kyowa Kirin Co., Ltd.120
招募中
1 期
A study of KK4277 in Healthy Volunteers, Patient with Systemic Lupus Erythematosus, and Patient with Cutaneous Lupus ErythematosusJPRN-jRCT2071220015Kinoshita Jun158
已完成
1 期
A study to primarily determine how safe and tolerable the study treatment, PTG-200 is in comparison to a matching placebo, when taken by healthy participants as a single dose or multiple dose treatment.Oral and Gastrointestinal - Crohn's diseaseCrohn's DiseaseACTRN12617001426370Protagonist Therapeutics82
尚未招募
1 期
A Phase 1, Randomized Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intermittent Consecutive Day Dosing Regimen of PRTX007 in Healthy Adultsassa VirusLassa VirusInfection - Other infectious diseasesACTRN12624000981527nited States Defense Threat Reduction Agency (DTRA)15
已完成
1 期
A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN1008Healthy VolunteersInflammatory and Immune System - Autoimmune diseasesACTRN12614000359639Clinical Network Services (CNS) Pty Ltd.108